Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 12Sarcoma 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

pembrolizumab 8Nivolumab 5avelumab 4Ipilimumab 4Radiotherapy 2Radiosurgery 2ALT-803 2tremelimumab 1talimogene laherparepvec 1sapanisertib 1prednylidene 1poly ICLC 1lenvatinib 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1deltacortene 1cemiplimab 1cabozantinib 1bempegaldesleukin 1atezolizumab 1Tacrolimus 1Radiation Dose Hypofractionation 1Radiation 1Prednisone 1Interferon-gamma 1Interferon-beta 1CTLA-4 Antigen 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Merkel Cell × talimogene laherparepvec × Clear all
NCT02819843 2025-01-29

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
19 enrolled 7 charts
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡